Chimerix to Report Fourth Quarter and Year End 2020 Financial Results and Provide an Operational Update on February 25, 2021

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) announced a live conference call on February 25, 2021, at 8:30 a.m. ET to discuss its fourth-quarter and full-year financial results ending December 31, 2020. The call will include a business overview, with access available via phone or webcast. Chimerix focuses on developing medicines for serious diseases, with ongoing programs for BCV, ONC201, and DSTAT. Notably, BCV is under review for regulatory approval, and ONC201 is in a registrational trial for glioma. The company remains committed to advancing innovative therapies, reflecting its dedication to patients.

Positive

• BCV is under review for regulatory approval, indicating potential for future revenue.
• ONC201 is in a registrational trial, with results expected later this year, which could lead to accelerated approval.

Negative

• Risks associated with ONC201's Phase 2 clinical trial data may not support regulatory approval.
• The potential benefits of acquiring Oncoceutics may not be realized.

DURHAM, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, February 25, 2021 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2020, and to provide a business overview.

To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 1478364. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Our three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the timing of the confirmatory response rate assessment for ONC201; the sufficiency of the data from the current Phase 2 clinical trial of ONC201 to support accelerated regulatory approval; the anticipated benefits of Chimerix’s acquisition of Oncoceutics; the completion of a Phase 3 study in acute myeloid leukemia with DSTAT; Chimerix’s ability to obtain regulatory approval for its clinical candidates, including DSTAT, ONC201 and BCV; and Chimerix’s ability to enter into a procurement agreement for the sale of BCV to the SNS. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that the current Phase 2 clinical trial data for ONC201 will not support accelerated, or any, regulatory approval; the anticipated benefits of the acquisition of Oncoceutics may not be realized; BCV may not obtain regulatory approval from the FDA or such approval may be delayed or conditioned; risks that Chimerix will not obtain a procurement contract for BCV in smallpox in a timely manner or at all; Chimerix’s reliance on a sole source third-party manufacturer for drug supply; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACT:

Investor Relations:        
Michelle LaSpaluto
919-972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Media:
David Schull
Russo Partners
858-717-2310
David.Schull@russopartnersllc.com

FAQ

When will Chimerix report its financial results for Q4 2020?

Chimerix will report its Q4 2020 financial results on February 25, 2021.

What is the focus of Chimerix's pipeline?

Chimerix's pipeline focuses on developing treatments for serious diseases, including cancer and smallpox.

What clinical trials are currently underway for Chimerix?

Chimerix is conducting clinical trials for BCV, ONC201, and DSTAT.

What is the significance of the upcoming ONC201 trial results?

The results from the ongoing ONC201 trial could lead to accelerated regulatory approval if the data is favorable.